Latest Development in Melanoma Research
A special issue of Cancers (ISSN 2072-6694).
Deadline for manuscript submissions: closed (25 March 2023) | Viewed by 54605
Special Issue Editors
Interests: melanoma; signal transduction; targeted therapies; drug resistance; MAPK; PI3K; cAMP
Special Issues, Collections and Topics in MDPI journals
Interests: melanoma; Merkel cell carcinoma; Kaposi's sarcoma; targeted therapies; immunotherapies; clinical trials; translational research
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Melanoma is the most aggressive and treatment-resistant skin cancer. In the last few decades, the therapeutic landscape for melanoma has evolved drastically due to a better understanding of the molecular changes occurring during the progression of melanoma. Four distinct melanoma categories are now defined based on their main genetic driver: BRAF (v-RAF murine sarcoma viral oncogene homolog B1) mutated, NRAS (neuroblastoma RAS viral oncogene homolog) mutated, NF1 (neurofibromin 1) mutated and triple negative. BRAF/MEK inhibitors have changed the treatment outcome in patients with BRAF-mutated melanoma with prolonged overall survival and progression-free survival. Concomitantly, a profound understanding of the interaction of melanoma cells with the immune system has fueled the development of immunotherapies for the treatment of advanced melanoma. Systemic treatments based on immune checkpoint inhibitors (ICIs) have dramatically improved outcomes for patients with advanced melanoma. However, despite recent advances in therapeutic management by targeted- and immunotherapies, the majority of patients will ultimately relapse because of primary and acquired resistance to treatments.
Metastatic melanoma remains one of the deadliest cancers; hence, improving overall survival will require a deep understanding of the molecular and cellular features of melanoma cells and their permissive microenvironment. In the present thematic issue, we want to summarize the recent advancements in melanoma therapy and highlight opportunities for therapeutic interventions that will improve the survival rates of metastatic melanoma patients as well as stage II and III patients at high risk of recurrence. This Special Issue welcomes reviews, as well as original research articles, on the latest development of melanoma research.
Dr. Nicolas Dumaz
Prof. Dr. Celeste Lebbe
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- melanoma
- targeted therapies
- immunotherapies
- resistance
- therapeutic targets
- tumor microenvironment
- signaling pathways
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.